Compugen to Present at Upcoming September 2020 Investor Conferences

Rhea-AI Summary

Compugen Ltd. (NASDAQ: CGEN) announced its participation in two upcoming virtual investor conferences. The first event is the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 16, 2020, at 9:30 AM ET. The second event is the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020, at 9:10 AM ET. Live webcasts of both presentations will be available on the Compugen website, with replays accessible afterward.

Compugen is focused on developing therapeutics in cancer immunotherapy, with lead candidates undergoing clinical trials.

HOLON, Israel, Sept. 3, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the following upcoming virtual investor conferences:

Event: Morgan Stanley Virtual 18^th Annual Global Healthcare Conference
Date: Wednesday, September 16, 2020
Presentation Time: 9:30 AM ET

Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday, September 22, 2020
Presentation Time: 9:10 AM ET

A live webcast of each presentation will be accessible in the Investor Relations section of the Compugen website at www.cgen.com. Replays will also be available following each live event.

About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. The Company's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. The Company's shares are listed on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.

Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124

Investor Relations contact:
Bob Yedid
LifeSci Advisors, LLC
Email: bob@lifesciadvisors.com 
Tel: +1 (646) 597-6989

Media contact:
Josephine Belluardo, Ph.D.
LifeSci Communications
Email: jo@lifescicomms.com
Tel: +1 (646) 751-4361

View original content:http://www.prnewswire.com/news-releases/compugen-to-present-at-upcoming-september-2020-investor-conferences-301123707.html

SOURCE Compugen Ltd.

FAQ

When will Compugen present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference?

Compugen will present on September 16, 2020, at 9:30 AM ET.

What is the date of Compugen's presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit?

Compugen will present on September 22, 2020, at 9:10 AM ET.

Where can I watch Compugen's investor conference presentations?

Live webcasts of Compugen's presentations will be available on their website at www.cgen.com.

What is Compugen's focus in therapeutic development?

Compugen focuses on the discovery and development of therapeutics in cancer immunotherapy.

What are the lead product candidates of Compugen?

Compugen's lead candidates include COM701, an anti-PVRIG antibody, and COM902, which targets TIGIT.